TR200001250T2 - Ati-CD40L bileşikleri ile lupus nefritis tedavisi - Google Patents

Ati-CD40L bileşikleri ile lupus nefritis tedavisi

Info

Publication number
TR200001250T2
TR200001250T2 TR2000/01250T TR200001250T TR200001250T2 TR 200001250 T2 TR200001250 T2 TR 200001250T2 TR 2000/01250 T TR2000/01250 T TR 2000/01250T TR 200001250 T TR200001250 T TR 200001250T TR 200001250 T2 TR200001250 T2 TR 200001250T2
Authority
TR
Turkey
Prior art keywords
ati
treatment
cd40l compounds
lupus nephritis
immune complex
Prior art date
Application number
TR2000/01250T
Other languages
English (en)
Inventor
L. Kalled Susan
W. Thomas Dav�D
Original Assignee
Biogen, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc filed Critical Biogen, Inc
Publication of TR200001250T2 publication Critical patent/TR200001250T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Immün kompleks hastaliklarla baglantili nefriti anti-CD40L bilesikleriyle tedaviye yönelik yöntemler öngörülmektedir. Teskil örneklerinden birinde immün kompleks hastaligi olan böbrek allografti yapilmis bir hastaya, nakil yapilan böbrek içinde immün kompleks glomerülonefrit olusmasini önlemek için anti-CD40L bilesikleri verilmistir..
TR2000/01250T 1997-01-10 1997-12-31 Ati-CD40L bileşikleri ile lupus nefritis tedavisi TR200001250T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3467397P 1997-01-10 1997-01-10

Publications (1)

Publication Number Publication Date
TR200001250T2 true TR200001250T2 (tr) 2001-03-21

Family

ID=21877889

Family Applications (7)

Application Number Title Priority Date Filing Date
TR2000/01248T TR200001248T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi
TR2000/01250T TR200001250T2 (tr) 1997-01-10 1997-12-31 Ati-CD40L bileşikleri ile lupus nefritis tedavisi
TR1999/02191T TR199902191T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bilesikleri ile lupus nefritis tedavisi
TR2000/01246T TR200001246T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi
TR2000/01247T TR200001247T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi.
TR2000/01249T TR200001249T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi
TR2000/01251T TR200001251T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2000/01248T TR200001248T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi

Family Applications After (5)

Application Number Title Priority Date Filing Date
TR1999/02191T TR199902191T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bilesikleri ile lupus nefritis tedavisi
TR2000/01246T TR200001246T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi
TR2000/01247T TR200001247T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi.
TR2000/01249T TR200001249T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi
TR2000/01251T TR200001251T2 (tr) 1997-01-10 1997-12-31 Anti-CD40L bileşikleri ile lupus nefritis tedavisi

Country Status (19)

Country Link
US (2) US20030031668A1 (tr)
EP (2) EP0948355A1 (tr)
JP (1) JP2001508441A (tr)
KR (2) KR100618081B1 (tr)
CN (2) CN1247472A (tr)
AU (1) AU5709798A (tr)
BR (1) BR9714523A (tr)
CA (1) CA2277222A1 (tr)
CZ (1) CZ297680B6 (tr)
EA (2) EA200501076A1 (tr)
EE (1) EE9900273A (tr)
HU (1) HUP0000833A3 (tr)
IL (1) IL130784A0 (tr)
IS (1) IS5100A (tr)
NO (1) NO993274L (tr)
NZ (1) NZ337072A (tr)
PL (1) PL190663B1 (tr)
TR (7) TR200001248T2 (tr)
WO (1) WO1998030240A1 (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP1067954A4 (en) * 1998-04-03 2004-08-18 Dartmouth College USE OF ANTI-GP39 ANTIBODIES FOR TREATING AND / OR REGRESSING LUPUS AND RELATED KIDNEY DISEASE
IL126681A0 (en) * 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
MXPA01006006A (es) 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
AU2001249182A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
CN100369932C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人cd154单克隆抗体及其应用
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
JP2012511014A (ja) 2008-12-05 2012-05-17 エイエルエス・セラピー・デベロップメント・インスティテュート 神経変成疾患を治療する方法
US20130310266A1 (en) * 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
JP2018526443A (ja) * 2015-08-31 2018-09-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法
AU2018271915A1 (en) 2017-05-24 2019-11-28 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
AU1748897A (en) * 1996-01-16 1997-08-11 Biogen, Inc. Therapeutic applications of T-BAM (CD40-L) technology to treat inflammatory kidney diseases
WO1997034473A1 (en) * 1996-03-21 1997-09-25 The Trustees Of Columbia University In The City Of New York Craf1 (traf-3) isoforms and uses thereof

Also Published As

Publication number Publication date
TR200001248T2 (tr) 2000-07-21
TR200001247T2 (tr) 2002-06-21
TR200001249T2 (tr) 2000-11-21
EP0948355A1 (en) 1999-10-13
HUP0000833A2 (en) 2000-07-28
KR20000070034A (ko) 2000-11-25
CN1247472A (zh) 2000-03-15
TR200001251T2 (tr) 2000-09-21
EP1357131A3 (en) 2004-02-11
IS5100A (is) 1999-06-30
CN1572325A (zh) 2005-02-02
WO1998030240A1 (en) 1998-07-16
HUP0000833A3 (en) 2001-09-28
US20030031668A1 (en) 2003-02-13
EP1357131A2 (en) 2003-10-29
BR9714523A (pt) 2000-05-02
IL130784A0 (en) 2001-01-28
PL190663B1 (pl) 2005-12-30
NO993274D0 (no) 1999-07-01
KR100618081B1 (ko) 2006-08-30
EA199900636A1 (ru) 2000-02-28
KR20050089165A (ko) 2005-09-07
EE9900273A (et) 2000-02-15
CZ244499A3 (cs) 1999-10-13
NO993274L (no) 1999-09-10
TR200001246T2 (tr) 2000-07-21
CA2277222A1 (en) 1998-07-16
NZ337072A (en) 2000-12-22
EA200501076A1 (ru) 2006-06-30
EA006314B1 (ru) 2005-10-27
US20070190053A1 (en) 2007-08-16
AU5709798A (en) 1998-08-03
PL334495A1 (en) 2000-02-28
JP2001508441A (ja) 2001-06-26
TR199902191T2 (tr) 1999-12-21
CZ297680B6 (cs) 2007-03-07

Similar Documents

Publication Publication Date Title
TR200001250T2 (tr) Ati-CD40L bileşikleri ile lupus nefritis tedavisi
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
CY1113600T1 (el) Θεραπειες συνδυασμου για λεμφωματα β-κυτταρου που περιλαμβανουν χορηγηση anti-cd20 αντισωματος
DE60124085D1 (de) Pde-v hemmer zur behandlung von morbus parkinson
MA27838A1 (fr) Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-alpha
EA199700116A1 (ru) Трициклические бензазепины как антагонисты вазопрессина, способ их получения, фармкомпозиция на их основе и способ лечения
DE602004022982D1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
FR2391183A1 (fr) Hydroxyalkylphenones et leur application comme photosensibilisateurs
MX9700430A (es) El uso de compuestos heterociclicos.
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
NO965336L (no) Undertrykkelse av tomurcellevekst med syndecan-1 ektodomene
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE50002119D1 (de) Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen
TR199801797T2 (tr) Iki kutuplu bozukluk tedavisi.
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ATE297745T1 (de) Chemische modifizierung von harn von säugern